Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

Archives of Dermatology
Debra BrenemanVictor J Stevens

Abstract

To evaluate the safety, dose tolerance, and efficacy of topical bexarotene gel in patients with early-stage cutaneous T-cell lymphoma (CTCL). Phase 1 and 2, open-label, dose-escalation clinical trial of bexarotene gel. Three university-based clinics. Sixty-seven adults with early-stage (TNM stages IA-IIA) CTCL. Bexarotene gel, 0.1%, 0.5%, and 1.0%, applied in incremental dose adjustments from 0.1% gel every day to 1.0% gel 4 times daily or the maximal tolerated dose. Patients were followed for efficacy and safety, and treatment continued as long as they benefited. Response (> or =50% improvement) was evaluated by the Physician's Global Assessment of cutaneous disease and by an overall severity assessment of cutaneous disease, including signs of CTCL and area involved. Most patients tolerated topical bexarotene at 1% gel twice daily for routine use. Adverse events were generally mild to moderate in severity and were confined to treatment sites. Treatment-limiting toxic effects were associated with skin irritation and increased with gel exposure. Patients achieved an overall response rate of 63% and a clinical complete response rate of 21%. Median projected time to onset of response was 20.1 weeks (range, 4.0-86.0 weeks), and the...Continue Reading

Citations

Feb 9, 2012·Current Treatment Options in Oncology·Tara BloomSteven T Rosen
Jul 21, 2004·Clinics in Dermatology·Elizabeth Knobler
Feb 28, 2004·Journal of the American Academy of Dermatology·Shelley Sekula-GibbsLaura Otillar
Mar 23, 2004·Journal of the American Academy of Dermatology·Narin ApisarnthanaraxMadeleine Duvic
Oct 25, 2003·Journal of the American Academy of Dermatology·Peter HealdUNKNOWN Worldwide Bexarotene Study Group
Aug 18, 2004·Current Opinion in Oncology·Francine Foss
Aug 22, 2009·Blood·H Miles PrinceRichard T Hoppe
Apr 30, 2002·American Journal of Clinical Dermatology·Narin ApisarnthanaraxMadeleine Duvic
Jun 1, 2006·American Journal of Clinical Dermatology·Margit A HuberKarin Scharffetter-Kochanek
Feb 20, 2010·Drugs·Frederick Lansigan, Francine M Foss
Jun 18, 2014·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Ercole MazzeoFilippo Bertoni
Jun 30, 2004·Leukemia & Lymphoma·D A PichardoS T Rosen
Nov 19, 2010·Expert Review of Hematology·Jasmine ZainOwen A O'Connor
Jun 10, 2008·Expert Opinion on Emerging Drugs·Dominik Sebastian MestelWolfram Sterry
Apr 26, 2006·Expert Opinion on Pharmacotherapy·Christiane QuerfeldJoan Guitart
Nov 8, 2008·Expert Opinion on Biological Therapy·Dominik Sebastian MestelChalid Assaf
Jun 7, 2005·Expert Opinion on Emerging Drugs·Reinhard Dummer
Apr 10, 2012·Seminars in Oncology·Benedetta BelloniReinhard Dummer
Nov 3, 2010·Journal of the American Academy of Dermatology·Ming Yang BiMadeleine Duvic
Oct 29, 2008·Hematology/oncology Clinics of North America·Frederick LansiganFrancine M Foss
Mar 8, 2008·Current Problems in Cancer·Benjamin D Smith, Lynn D Wilson
Oct 24, 2007·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniLorenzo Cerroni
Dec 19, 2007·Seminars in Oncology·Madeleine Duvic, Francine M Foss
Oct 23, 2009·Dermatologic Therapy·John A Zic
Feb 21, 2006·Clinical and Experimental Dermatology·J J Scarisbrick
Jan 8, 2009·International Journal of Dermatology·Stuart R LessinHong Wu
Oct 4, 2006·Dermatologic Therapy·Chunlei Zhang, Madeleine Duvic
Jan 12, 2007·International Journal of Dermatology·Patsy LenaneS O'Loughlin
May 12, 2006·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Claus-Detlev KlemkeJürgen C Becker
Oct 9, 2013·Dermatologic Therapy·Courtney R Schadt
Oct 13, 2011·American Journal of Hematology·Ryan A Wilcox
Oct 23, 2009·Experimental Dermatology·Anne Chantal KnolBrigitte Dréno
Jan 22, 2013·Veterinary Dermatology·Pamela D Martin, David J Argyle
Jan 21, 2014·The Journal of Dermatology·Keiji IwatsukiUNKNOWN Japanese Skin Cancer Society - Lymphoma Study Group
Jun 4, 2014·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Susanne Dugas-BreitChristian Hallermann
Mar 7, 2006·Seminars in Oncology·Joan Guitart
Mar 7, 2006·Seminars in Oncology·Rudolf Stadler, Almut Kremer
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franz TrautingerSean Whittaker
May 20, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·V McFarlaneT M Illidge
Oct 5, 2015·Dermatologic Clinics·Cuong V Nguyen, Kimberly A Bohjanen
Jan 21, 2014·Journal of the American Academy of Dermatology·Sarah I JawedChristiane Querfeld
Oct 4, 2016·Clinical Lymphoma, Myeloma & Leukemia·Mudit ChowdharyGaurav Marwaha

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.